Using Entity Metrics to Understand Drug Repurposing.
- 30 May 2020
- journal article
- Vol. 2020, 377-382
Abstract
Understanding the process of drug repurposing is critically significant for drug development. In this paper, we employ extracted bio-entities to detect the features of different phases in drug repurposing. We proposed a transparent and easy entitymetric indicator for bio-entities, i.e., Popularity Index, to quantify and visualize the dynamic changes in academic interests of bio-entities. By taking aspirin as an example, the results display specific profiles of drug repurposing and the evolution of bio-entities in the different phases of drug research, which would potentially be valuable for pharmaceutical companies and scholars to successfully discover and repurpose drugs.Keywords
This publication has 24 references indexed in Scilit:
- Detecting Potential Adverse Drug Reactions Using a Deep Neural Network ModelJournal of Medical Internet Research, 2019
- Drug repurposing: progress, challenges and recommendationsNature Reviews Drug Discovery, 2018
- A bibliometric review of drug repurposingDrug Discovery Today, 2018
- Automating drug discoveryNature Reviews Drug Discovery, 2017
- Entitymetrics: Measuring the Impact of EntitiesPLOS ONE, 2013
- Using literature-based discovery to identify novel therapeutic approaches.Cardiovascular & Hematological Agents in Medicinal Chemistry, 2013
- Drug repurposing and adverse event prediction using high‐throughput literature analysisWires Systems Biology and Medicine, 2011
- Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trialsHeart, 2001
- Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study.1988
- EFFECTS OF SALICYLATES ON HUMAN PLATELETSThe Lancet, 1968